ECP-1014 / Euclises Pharma - LARVOL DELTA

ECP-1014 Treatment for Patients With Solid Tumor Cancers (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Euclises Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2022 ➔ Dec 2023 | Trial primary completion date: Jun 2022 ➔ Sep 2023

Enrollment open • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PTGS2